Overview

Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Nave AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-20

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy and safety of selinexor-based chemotherapy-sparing regimens (including chemotherapy-free or dose-reduced approaches) in optimizing therapeutic strategies for treatment-nave acute myeloid leukemia patients deemed unfit for intensive induction therapy. The investigation will focus on dynamic blast clearance patterns and early toxicity profiles to inform timely treatment adaptation during the critical induction window.

Phase:

Details

Lead Sponsor:

Donghua Zhang